Abstract:It has been well established that cancer cells can evade immune surveillance by mutating themselves. Understanding genetic alterations in cancer cells that contribute to immune regulation could lead to better immunotherapy patient stratification and identification of novel immune-oncology (IO) targets. In this report, we describe our effort of genome-wide association analyses across 22 TCGA cancer types to explore the associations between genetic alterations in cancer cells and 76 immune traits. Results showed that the tumor microenvironment (TME) is shaped by different gene mutations in different cancer types. Out of the key genes that drive multiple immune traits, top hit KEAP1 in lung adenocarcinoma (LUAD) was selected for validation. It was found that KEAP1 mutations can explain more than 10% of the variance for multiple immune traits in LUAD. Using public scRNA-seq data, further analysis confirmed that KEAP1 mutations activate the NRF2 pathway and promote a suppressive TME. The activation of the NRF2 pathway is negatively correlated with lower T cell infiltration and higher T cell exhaustion. Meanwhile, several immune check point genes, such as CD274 (PD-L1), are highly expressed in NRF2-activated cancer cells. By integrating multiple RNA-seq data, a NRF2 gene signature was curated, which predicts anti-PD1 therapy response better than CD274 gene alone in a mixed cohort of different subtypes of non-small cell lung cancer (NSCLC) including LUAD, highlighting the important role of KEAP1-NRF2 axis in shaping the TME in NSCLC. Finally, a list of overexpressed ligands in NRF2 pathway activated cancer cells were identified and could potentially be targeted for TME remodeling in LUAD. Recent studies have found that some genetic changes help cancer cells to evade the immune surveillance. To systematically understand the impact of cancer cell genetic alterations to immune regulation, we examined 76 immune traits across 22 cancer types. The tumor microenvironment (TME), crucial for cancer development, varies based on gene mutations in different cancers. Notably, the KEAP1 gene in lung adenocarcinoma (LUAD) emerged as a key player, explaining over 10% of immune trait variations. KEAP1 mutations activate the NRF2 pathway, creating a suppressive TME in LUAD with lower T cell infiltration and heightened T cell exhaustion. Additionally, genes such as CD274 (PD-L1), associated with immune checkpoints, exhibit high expression in NRF2-activated cancer cells. By developing a NRF2 gene signature, we found that it more effectively predicts anti-PD1 therapy responses than CD274 alone in non-small cell lung cancer. Lastly, we identified ligands overexpressed in NRF2-activated cancer cells, suggesting potential targets for reshaping the LUAD microenvironment. In essence, understanding these genetic interactions helps improve lung cancer treatment and enhance the efficacy of immunotherapy.

Aberrant R-loop–mediated immune evasion, cellular communication, and metabolic reprogramming affect cancer progression: a single-cell analysis

Abstract 2389: LINC00901 Regulates Glucose Metabolism in Pancreatic Cancer

Advancements and Challenges of R-loops in Cancers: Biological Insights and Future Directions

Association of R-loop binding proteins with prognosis and anti-tumor drug sensitivity in lung adenocarcinoma: a bioinfor-matic study

R Loops and Their Composite Cancer Connections

Multicenter cohort analysis of anoikis and EMT: implications for prognosis and therapy in lung adenocarcinoma

R-Loop Functions in -Associated Mammary Tumorigenesis

Aberrant super-enhancer landscape reveals core transcriptional regulatory circuitry in lung adenocarcinoma

Abstract 3019: Dissecting in vivo functions of R-Loops in Brca1 -associated DNA replication stress and mammary tumorigenesis

Identification of tumor heterogeneity associated with KRAS/TP53 co-mutation status in lung adenocarcinoma based on single-cell RNA sequencing

Co-transcriptional R-loops-mediated epigenetic regulation drives growth retardation and docetaxel chemosensitivity enhancement in advanced prostate cancer

Non-coding RNA LINC00857 is predictive of poor patient survival and promotes tumor progression via cell cycle regulation in lung cancer

R-loop and diseases: the cell cycle matters

R-loop functions in Brca1-associated mammary tumorigenesis

Single‐cell transcriptomic analysis reveals circadian rhythm disruption associated with poor prognosis and drug‐resistance in lung adenocarcinoma

Unveiling the impact of cell death-related genes and immune dynamics on drug resistance in lung adenocarcinoma: a risk score model and functional insights

LINC00460/miR-186-3p/MYC feedback loop facilitates colorectal cancer immune escape by enhancing CD47 and PD-L1 expressions

A Cohesin-Mediated Intrachromosomal Loop Drives Oncogenic ROR lncRNA to Accelerate Tumorigenesis.

Exploring the function and prognostic value of RPLP0, RPLP1 and RPLP2 expression in lung adenocarcinoma

Genome-wide analyses reveal the contribution of somatic variants to the immune landscape of multiple cancer types

Glycolysis-Related LINC02432/Hsa-miR-98–5p/HK2 Axis Inhibits Ferroptosis and Predicts Immune Infiltration, Tumor Mutation Burden, and Drug Sensitivity in Pancreatic Adenocarcinoma